Table 3.

Changes in Schedule II CNS stimulant use, 2013 and 2018

	Persons, number who took CNS stimulants
	2013	2018	Difference	95% CI		T	P	Change t1–t2,(%)
All adults	2 296 473	4 128 752	1 832 279	1 006 626	2 657 932	4.35	<0.01	79.8
Gender
Male	1 315 701	1 827 177	511 476	- 28 416	1 051 368	1.86	0.063	38.9
Female	980 772	2 301 574	1 320 802	840 273	1 801 333	5.39	<0.01	134.7
Age group (years)
19–24	578 917	772 502	193 585	- 224 956	612 126	0.91	0.365	33.4
25–44	1 033 683	1 914 712	881 029	394 685	1 367 372	3.55	<0.01	85.2
45–64	581 227	1 166 798	585 571	284 399	886 745	3.81	<0.01	100.7
65–85	102 646	274 739	172 093	35 088	309 099	2.46	0.014	167.7

	Stimulant prescriptions, number dispensed
	2013	2018	Difference	95% CI			p	Change t1–t2 (%)
All schedule II stimulants	15 412 693	30 150 428	14 737 735	12 105 049	17 370 420	10.97	<0.01	95.6
Amphetamine products	10 859 022	23 803 206	12 944 184	10 518 473	15 369 896	10.46	<0.01	119.2
Methylphenidate products	4 553 672	6 347 222	1 793 550	244 341	3 342 759	2.27	0.023	39.4

CNS, central nervous system.